Tiziana Life Sciences Plc

[Available On-Demand]
Developing innovative therapeutics for Crohn's Disease, Progressive MS, HCC and COVID-19. Our proprietary technologies for oral, nasal and inhalation administration of antibodies could potentially be transformational for immunotherapies.

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Currently in Phase 2 trials in Crohn's and Pro-MS. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
Ticker:
TLSA
Exchange:
NASDAQ
Company Type:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Foralumab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO/CSO
Tiziana Life Sciences